• Clinical Outcomes of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Stent Versus Standard Drug-Eluting Coronary Stents: A Meta-Analysis

    Highlights

    • Combo DTS vs. 2nd generation DES had higher 1-year target lesion revascularization.
    • No significant difference in 1-year: cardiac death, target lesion failure
    • No significant difference in 1-year: stent thrombosis, target vessel failure, and myocardial infarction
    • No significant difference in 2-year: cardiac death, target lesion failure, and target lesion revascularization

    Abstract

    Background

    Coronary stent neoatherosclerosis, thrombosis, and restenosis remain significant concerns with new-generation drug-eluting stents (DES). The Dual-Therapy CD34 antibody-covered sirolimus-eluting stent [dual therapy stent (DTS)] is a sirolimus-eluting stent with CD34 antibodies immobilized on its luminal surface to capture circulating endothelial progenitor cells and promote early endothelialization. We conducted a meta-analysis to determine whether the DTS was superior to standard DES.

    Methods

    We conducted a comprehensive search for controlled randomized and non-randomized studies. We presented data using risk ratios (95% confidence intervals) and measured heterogeneity using Higgins' I2.

    Results

    Five studies with a low risk of bias met the inclusion criteria, with a total of 1884 patients in the DTS and 1819 in standard DES arms. There was no difference between the 2 arms in the following 1-year outcomes: cardiac death [1% vs 0.9% RR 1.13 (95% CI 0.49–2.62) I2 = 0%], target lesion failure [6.2% vs 5.3% RR 1.12 (0.80–1.58) I2 = 0%], target lesion revascularization (TLR) [4.9% vs 3.4% RR 1.40 (0.93–2.10) I2 = 15%], target vessel failure [8.2% vs 6.1% RR 1.24 (0.75–2.04) I2 = 0%], target vessel myocardial infarction [1.1% vs 1.8% RR 0.73 (0.19–2.90) I2 = 62%] and stent thrombosis [0.4% vs 0.6% HR 0.85 (0.27–2.62) I2 = 0%]. However, compared with second-generation DES (EES and ZES), the DTS had significantly higher one-year TLR [5% vs. 3.1% RR 1.58 (1.02–2.46) P = 0.04 I2 = 0%].

    Conclusion

    One-year TLR was significantly higher in the DTS arm compared with second-generation DES. There was no difference in the other 1-year clinical outcomes compared with standard DES.

    Author bio

    Cardiovascular Revascularization Medicine, 2020-02-01, Volume 21, Issue 2, Pages 213-221, Copyright © 2019 Elsevier Inc.

     

    Source:

    Read the full article on Science Direct: Clinical Outcomes of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Stent Versus Standard Drug-Eluting Coronary Stents: A Meta-Analysis

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details